- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- November 2023
- 184 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Report
- September 2020
- 194 Pages
Global
From €3079EUR$3,185USD£2,645GBP
€4399EUR$4,550USD£3,778GBP
- Report
- April 2021
- 122 Pages
Global
From €10630EUR$10,995USD£9,130GBP
- Report
- March 2019
- 47 Pages
Global
From €3379EUR$3,495USD£2,902GBP
- Report
- November 2018
- 46 Pages
Global
From €6187EUR$6,400USD£5,315GBP
- Drug Pipelines
- December 2019
- 70 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- December 2022
- 50 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- May 2023
- 238 Pages
Global
From €5540EUR$5,730USD£4,758GBP
The Phosphate Binder market is a subset of the larger Liver and Kidney Disorders Drugs market. It is composed of drugs that are used to reduce the amount of phosphate in the blood, which can be caused by kidney or liver disorders. These drugs are typically taken orally and bind to phosphate in the gut, preventing it from being absorbed into the bloodstream. Common side effects of phosphate binders include constipation, nausea, and vomiting.
Phosphate binders are used to treat a variety of conditions, including chronic kidney disease, hyperphosphatemia, and hypoparathyroidism. They are also used to prevent complications from dialysis, such as calcification of the blood vessels.
Some of the major companies in the Phosphate Binder market include Sanofi, AstraZeneca, Daiichi Sankyo, and Takeda Pharmaceuticals. Other companies include AbbVie, Amgen, and Novartis. Show Less Read more
